Skip to main content
OpenTrials
Completed

NCT Number: NCT03399214

Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects

The objective of the study is to assess the dose dependent changes in MRI signal intensity (SI) in liver after IOP Injection intravenous administration in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Taipei Veterans General Hospital

Taipei County, 112, Taiwan

About this study

Find the max. signal change after IOP administration

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male, age ≥ 20 ~40 years, BMI=18~27.
  • The biochemistry test results, complete blood count (CBC) test results, urinalysis test results, coagulation time test results must within normal range or considered clinically normal by the clinical investigator at screening.
  • Male subjects must take reliable contraceptive method(s) during and after the study for a period of 14 days.
  • No screening of drug or alcohol abuse within one year prior to study enrollment.
  • Subjects are willing to comply with the protocol and sign informed consent form.

Exclusion criteria

  • Subjects have serious allergic history or known allergy to MRI contrast agent.
  • Subjects with HBV, HCV, HIV.
  • Imaging and/or functional abnormalities of liver and/or spleen.
  • Subjects have alcohol or caffeine consumption within 48 hours prior to the administration of study contrast agent.
  • Subjects have electronically, magnetically and mechanically activated implanted devices.
  • Subjects have participated in other investigational trials or receive any contrast agents within 28 days prior to study enrollment.
  • Subjects with active systemic infections, active and clinically significant cardiac diseases, active gastrointestinal ulcers, or medical conditions that may significantly affect action, adequate absorption and elimination of investigational contrast agent.
  • Subjects have taken any food 6 hours prior to administration.

Treatment and study plan

IOP Injection

Drug

T1 and T2

Primary outcomes

  1. The Change of MRI SI (%) in vessels, liver, and spleen

    Time frame: Day1: within 60 mins after IOP administration

    The optimal imaging time of IOP injection for the maximum SI (%)

Secondary outcomes

  1. The changes from baseline in hematology data

    Time frame: within 14 days

    Complete blood count and differential count, Reticulocyte count

  2. The incidence of all treatment-related adverse events (TRAE)

    Time frame: within 14 days

Sponsors and collaborators

Lead sponsor

MegaPro Biomedical Co. Ltd.

Industry

Registry information

Official study title

A Phase Ib Study to Evaluate Safety and Efficacy Profiles of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Healthy Subjects.

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 16, 2018
Registry last updated
Aug 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.